TG Therapeutics Director Sagar Sells 20,852 Shares at $32.24 on Sept 11

TG Therapeutics, Inc. (TGTX) has announced that Director Lonial Sagar has recently sold 20,852 shares of the company at a price of $32.24 per share on September 11, 2025.

TG Therapeutics, Inc. (TGTX) has announced that Director Sagar Lonial sold 20,852 shares of the company on September 11, 2025, at a weighted average price of $32.24 per share, totaling $672,268. The transaction was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission (SEC). Following the sale, Lonial directly owns 94,061 shares of TG Therapeutics.

The sale was conducted to satisfy income tax obligations related to restricted stock. This move comes as a routine financial decision for executives to manage their tax liabilities, rather than a reflection on the company's financial health or future prospects.

The transaction occurred at a price per share that is slightly below the company's recent trading average, indicating a neutral market sentiment towards TG Therapeutics. The sale did not significantly impact the overall share count, as Lonial's ownership remains at 94,061 shares out of the total 218,128 shares outstanding.

Investors should closely monitor the company's ongoing clinical trials and financial performance to gauge the true value of TG Therapeutics. The recent sale by Lonial should not be seen as a cause for concern, but rather as a standard practice for executives managing their personal finances.